Uzbekistan's mental health system is undergoing significant reform aimed at improving care and service delivery. This article provides a comprehensive evaluation of the current state of Uzbekistan's mental health system using the WHO 2010 monitoring and evaluation framework. It also details ongoing reforms designed to address systemic issues, enhance mental healthcare and ensure better health outcomes for the population.

A clinical research team’s goal is to support the implementation, conduct, and monitoring of research studies and corresponding protocols. There is a need to ensure that study teams have adequate resources and regulatory support to successfully adhere to regulations and good clinical research practices. Our team, the UC Davis Division of Infectious Diseases Research Unit (IDRU), sought to establish a One Signature Initiative program for all studies and protocols supported by the IDRU. The One Signature Initiative designates one point of contact from each ancillary team or department to sign delegation and training logs, who in turn is delegated to train their team. The goals of the One Signature Initiative were, and are still, to reduce task redundancy, lessen regulatory burden on research teams, and minimize audit findings. Since the implementation of the One Signature Initiative in 2023, acceptance has been favorable, and we have expanded its footprint by incorporating it into our standard operating procedures. This article discusses our experiences, and ancillary departments’ experiences, with the One Signature Initiative. Our experience is an example of how a One Signature Initiative can be developed that is efficient, effective, and well-accepted by clinical research stakeholders.

Herbicide resistance in weeds significantly threatens crop production in the United States. The introduction of dicamba-resistant soybean and cotton stacked with other herbicide tolerance traits has provided farmers with the flexibility of having multiple herbicide options to diversify their weed management practices and delay resistance evolution. XtendiMax® herbicide with VaporGrip® Technology is a dicamba formulation registered for use on dicamba-resistant soybean and cotton crops by the U.S. Environmental Protection Agency (EPA). One of the terms of its registration includes an evaluation of inquiries on reduced weed control efficacy by growers or users of XtendiMax for suspected weed resistance. A total of 3,555 product performance inquiries (PPIs) were received from 2018 to 2021 regarding reduced weed control efficacy by dicamba. Following the criteria recommended by EPA for screening of suspected resistance in the field, a total of 103 weed accessions from 63 counties in 13 states were collected for greenhouse testing over those 4 yr. Weed accessions for greenhouse testing were collected only in states where resistance to dicamba was not yet confirmed in the weed species under investigation. The accessions, which consisted primarily of waterhemp and Palmer amaranth, were treated with dicamba at rates of 560 g ae ha−1 and 1,120 g ae ha−1. All weed accessions, except for one accession each of Palmer amaranth and waterhemp, were controlled by ≥90% with dicamba at 21 d after treatment in the greenhouse.

Egilman et al. review the current data sharing practices of three global regulatory agencies — Health Canada, the European Medicines Agency and the Food and Drug Agency. While there has been progress towards increasing transparency over the past decade, progress has been slow.

Biospecimen repositories play a vital role in enabling investigation of biologic mechanisms, identification of disease-related biomarkers, advances in diagnostic assays, recognition of microbial evolution, and characterization of new therapeutic targets for intervention. They rely on the complex integration of scientific need, regulatory oversight, quality control in collection, processing and tracking, and linkage to robust phenotype information. The COVID-19 pandemic amplified many of these considerations and illuminated new challenges, all while academic health centers were trying to adapt to unprecedented clinical demands and heightened research constraints not witnessed in over 100 years. The outbreak demanded rapid understanding of SARS-CoV-2 to develop diagnostics and therapeutics, prompting the immediate need for access to high quality, well-characterized COVID-19-associated biospecimens. We surveyed 60 Clinical and Translational Science Award (CTSA) hubs to better understand the strategies and barriers encountered in biobanking before and in response to the COVID-19 pandemic. Feedback revealed a major shift in biorepository model, specimen-acquisition and consent process from a combination of investigator-initiated and institutional protocols to an enterprise-serving strategy. CTSA hubs were well equipped to leverage established capacities and expertise to quickly respond to the scientific needs of this crisis through support of institutional approaches in biorepository management.

The tri-island state of Grenada, Carriacou, and Petit Martinique's legislative and institutional compliance with the World Organisation for Animal Health's (OIE) guidelines on antimicrobial utilisation in poultry production is reviewed in this paper. This includes legislative and other institutional documents, coupled with interviews with veterinary officers, health officers and managers of the veterinary drug distribution centres were conducted to evaluate the extent of Grenada's compliance with the OIE's Terrestrial Animal Health Code in the use of antimicrobials in poultry production. Five thematic areas were evaluated: 1) legislative and institutional arrangements; 2) surveillance and reporting; 3) risks associated with the importation of poultry meat products; 4) ante- and post-mortem inspection; and 5) procurement and use of antimicrobials. The information revealed that the current legislative framework in Grenada does not adequately address poultry food safety and that there is a need to strengthen the synergies between the agricultural and health sectors to enable a more thorough monitoring of antimicrobials use in poultry production. There is a need to strengthen epidemiology of zoonotic diseases, provisioning of education and information for key stakeholders about the use of antibiotics and the development of a system to monitor antibiotic procurement, distribution and use in Grenada. These findings have implications for other small island states in the Caribbean that have similar limitations in institutional capacity and knowledge deficits in the prudent use of antibiotics.

Manufacturers of several POST corn herbicides recommend tank-mixing their herbicides with atrazine to improve performance; however, future regulatory changes may place greater restrictions on atrazine use and limit its availability to growers. Our research objectives were to quantify the effects of tank-mixing atrazine with tembotrione compared to tembotrione alone on (1) weed control, (2) variability in weed control, and (3) sweet corn yield components and yield variability. Field studies were conducted for 2 yr each in Illinois, Oregon, Washington, and Ontario, Canada. Tembotrione at 31 g ha−1 was applied alone and with atrazine at 370 g ha−1 POST at the four- to five-collar stage of corn. The predominant weed species observed in the experiment were common to corn production, including large crabgrass, wild-proso millet, common lambsquarters, and velvetleaf. For nearly every weed species and species group, the addition of atrazine improved tembotrione performance by increasing mean levels of weed control 3 to 45% at 2 wk after treatment. Adding atrazine reduced variation (i.e., standard deviation) in control of the weed community by 45%. Sweet corn ear number and ear mass were 9 and 13% higher, respectively, and less variable when atrazine was applied with tembotrione, compared to tembotrione alone. Additional restrictions or the complete loss of atrazine for use in corn will necessitate major changes in sweet corn weed management systems.

Weed management systems used by sweet corn growers, including the role of atrazine, are poorly characterized. Management records of 175 fields throughout the major sweet corn production areas of the Midwest were surveyed from 2005 to 2007. Seventy-four percent of sweet corn fields in the Midwest were grown in rotation with soybean or corn. Interrow cultivation was used on 48% of fields, and atrazine use was higher in those fields without interrow cultivation. A majority of fields (54%) received both PRE and POST herbicide applications. Mesotrione was applied below the registered use rate in two-thirds of the fields in which it was used POST. Atrazine rates in sweet corn were highest when the preceding crops were other vegetables, compared to preceding crops of soybean or corn. Selective herbicides are used extensively in U.S. sweet corn production, accounting for 94% of total weed management expenditures which average $123/ha. Growers treated 66% of fields with one or more applications of atrazine at an average total use rate of 1.35 kg ai/ha. The estimated annual net cost to replace atrazine in U.S. sweet corn production with the broad spectrum broadleaf herbicide, mesotrione, is $9.2 million.

In the wake of the financial crisis considerable momentum has built up behind proposals to extend central counterparty (CCP) clearing in the over-the-counter derivatives markets. However, implementation is proving complex. This paper argues that one cause of this complexity is that the public sector is seeking to incorporate into legislation (and require the wider use of) a privately owned and operated risk management mechanism. As a matter of law, the paper argues that CCP clearing can be understood as a market-generated ‘legal device’; in other words, one designed to support the markets by means of the interaction of various private law techniques. Following this analysis through, the paper highlights the benefits and drawbacks which derive from the legal techniques underlying CCP clearing (standardisation of contracts, asset-backing, netting and so on) and argues that these qualities are inherent to the device. It concludes that the inherent capacity of CCP clearing gives rise to a qualitatively different set of challenges for policymakers to those arising from technical implementation and it explains that both types of problem need to be addressed if the CCP prescription is to be effective.

The development of new drugs to treat vascular dementia and other conditions in which cognitive impairment is due at least in part to vascular pathology will require future interaction among academic, industry, and government regulatory clinicians and scientists. This article offers the author's perspective on the positive involvement of the Food and Drug Administration in development of conceptual frameworks and practical approaches to treatment of conditions characterized by vascular burden of the brain.